Poster: Public Health

 General hepatology
 Public health

Poster Area

Poster
11 April 2019 09:00 - 19:00


Presentations

Title Time Appointment Abstract
THU-382 Use of facility-based provider initiated testing and counselling approach to ascertain viral hepatitis C status in high burden populations in Nigeria
11 April 2019 09:00 - 19:00
THU-383 Dried blood spots: A useful tool for virologically caracterising the hepatitis C virus epidemic
11 April 2019 09:00 - 19:00
THU-384 Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection
11 April 2019 09:00 - 19:00
THU-385 Targeted screening for hepatitis C and predictors of advanced liver disease in the birth cohort in a tertiary primary care clinic
11 April 2019 09:00 - 19:00
THU-386 Interim results of hepatitis prevention, control and elimination program in Ulaanbaatar, Mongolia
11 April 2019 09:00 - 19:00
THU-387 Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach
11 April 2019 09:00 - 19:00
THU-388 Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data
11 April 2019 09:00 - 19:00
THU-389 Assessment of hepatitis C screening strategies in different community settings in a Canadian metropolitan area
11 April 2019 09:00 - 19:00
THU-390 Results of a birth cohort hepatitis C screening program in an academic emergency department in Canada
11 April 2019 09:00 - 19:00
THU-391 Impact of early screening and treatment of hepatitis C virus and improvements in risk reduction on HCV transmission among HIV-infected men who have sex with men in France: A modeling approach
11 April 2019 09:00 - 19:00
THU-392 Building capacity within a hepatitis C treatment model. the validation process for a hepatitis C pre-treatment pharmacist assessment complex intervention toolkit
11 April 2019 09:00 - 19:00
THU-393 HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort
11 April 2019 09:00 - 19:00
THU-394 Cancer risk among people with HIV, HBV, and/or HCV infections
11 April 2019 09:00 - 19:00
THU-395 Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): Real world evidence of decreasing HCV incidence and prevalence
11 April 2019 09:00 - 19:00
THU-396 Hepatitis C screening among the population of Georgia within the national elimination program
11 April 2019 09:00 - 19:00
THU-397 Screening strategies for hepatitis C virus elimination in Italy
11 April 2019 09:00 - 19:00
THU-398 Circulating HCV resistant strains may result in long-term challenges to HCV elimination: A modeling study
11 April 2019 09:00 - 19:00
THU-399 First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates
11 April 2019 09:00 - 19:00
THU-400 Alanine-aminotransferase and 20-year risk of liver disease, cancer, ischemic heart disease, and diabetes in a Danish general population sample aged 30-49 years
11 April 2019 09:00 - 19:00
THU-401 Changes in mortality due to chronic liver diseases in Spain during the period 2002-2016
11 April 2019 09:00 - 19:00
THU-402 Tailored message interventions using social marketing approach versus traditional message for increasing participation in viral hepatitis screening  for Japanese workers
11 April 2019 09:00 - 19:00
THU-403 The consensus hepatitis C cascade of care: Methodology and initial findings from three countries
11 April 2019 09:00 - 19:00
THU-405 Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016
11 April 2019 09:00 - 19:00
THU-406 Cost-effectiveness analysis of "treat all" guidelines for chronic hepatitis C in Brazil
11 April 2019 09:00 - 19:00
THU-407 Implementation of a hepatitis C testing and linkage to care program in the Philadelphia jail system
11 April 2019 09:00 - 19:00
THU-408 Screening for viral immunity prior to immunosuppressive or biologic therapy
11 April 2019 09:00 - 19:00
THU-409 Progress on scaling up testing and treatment for hepatitis C elimination in Punjab, Pakistan: Hepatitis prevention and treatment program
11 April 2019 09:00 - 19:00
THU-410 Hepatitis B prevention of mother to child transmission integrated into antenatal care services in Mozambique
11 April 2019 09:00 - 19:00
THU-411 Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda
11 April 2019 09:00 - 19:00
THU-412 Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program
11 April 2019 09:00 - 19:00
THU-413 Service delivery for hepatitis C care: A systematic review and meta-analysis
11 April 2019 09:00 - 19:00
THU-414 Low rate of treatment uptake amongst recently released prisoners with active HCV infection
11 April 2019 09:00 - 19:00
THU-415 Changing patterns of liver disease in Wales: First results from the Wales liver disease registry
11 April 2019 09:00 - 19:00
THU-416 Use of telemedicine as a cost-effective program to achieve microelimination of hepatitis C virus infection among patients in a public healt care system in a low-income country
11 April 2019 09:00 - 19:00
THU-417 CURE-IT Program - Introducing equity, removing barriers and treating patients hepatitis C close to home: The Queensland experience
11 April 2019 09:00 - 19:00
THU-418 Community-based screening for significant liver fibrosis among apparently asymptomatic adults in Delhi
11 April 2019 09:00 - 19:00
THU-419 Prevalence of hepatitis B and C virus infections in Mongolian children and adolescents
11 April 2019 09:00 - 19:00
THU-420 Examination of patient and provider perceptions of hepatitis C care in Rwanda
11 April 2019 09:00 - 19:00
THU-421 Lower alcohol taxes are associated with increased liver transplant listing
11 April 2019 09:00 - 19:00
THU-422 Referral, treatment uptake and self-reported barriers in drug users diagnosed with active hepatitis C attending a low-threshold methadone program in Lisbon
11 April 2019 09:00 - 19:00
THU-423 Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe
11 April 2019 09:00 - 19:00
THU-424 HCV care cascade of PWIDs reached within the Global Fund needle and syringe program in Georgia
11 April 2019 09:00 - 19:00
THU-425 Questioning the concept of cure: The morbidity and mortality of a homeless population following HCV treatment
11 April 2019 09:00 - 19:00
THU-426 Further validation of a liver 'traffic light' test as a prediction model for survival and development of serious liver-related events
11 April 2019 09:00 - 19:00
THU-427 A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV program)
11 April 2019 09:00 - 19:00
THU-428 Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation
11 April 2019 09:00 - 19:00
THU-429 Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care
11 April 2019 09:00 - 19:00
THU-430 Changing prevalence of aetiological factors among Australians hospitalized for cirrhosis
11 April 2019 09:00 - 19:00
THU-431 The burgeoning growth in cirrhosis-related hospitalization in Australia, 2008-2016
11 April 2019 09:00 - 19:00
THU-432 Viral sustained response in chronic hepatitis C did not reduce short term heatlh expediture
11 April 2019 09:00 - 19:00
THU-433 Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment
11 April 2019 09:00 - 19:00
THU-434 Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily
11 April 2019 09:00 - 19:00
THU-435 A threshold analysis for the cost-effectiveness of hepatitis B and hepatitis C testing in emergency departments in the UK
11 April 2019 09:00 - 19:00
THU-436 The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the National Health Service health check programme for 40 to 74 year olds in England
11 April 2019 09:00 - 19:00
THU-437 The Global Epidemiology on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
11 April 2019 09:00 - 19:00
THU-438 The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis
11 April 2019 09:00 - 19:00
THU-439 Variability in liver function test results and the risk of heart disease and mortality: A nationwide population-based study
11 April 2019 09:00 - 19:00
THU-440 Changing incidence of reported hepatitis B and its different trends amongest age groups in china from 2004-2016
11 April 2019 09:00 - 19:00